Active surveillance in prostate cancer: The need to standardize

Tumor Biology

Volumn 32, Issue 5, 2011, Pages 839-843

  Filella, Xavier ^a   Alcover, Juan ^a   Molina, Rafael ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Active surveillance; Gleason score; Prostatic cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; BLOOD LEVEL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONSENSUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; IMMUNOASSAY; NOMOGRAM; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REFERENCE VALUE; REVIEW; SCORING SYSTEM; STANDARDIZATION; THERAPY DELAY;

EID: 80052306235     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0193-2     Document Type: Review

References (32)

1. A Jemal F Bray MM Center J Ferlay E Ward D Forman 2011 Global cancer statistics CA Cancer J Clin 61 69 90 21296855 10.3322/caac.20107
2. R Yatani I Chigusa K Akazaki GN Stemmermann RA Welsh P Correa 1982 Geographic pathology of latent prostatic carcinoma Int J Cancer 29 611 616 7107064 10.1002/ijc.2910290602 1:STN:280:DyaL383msVequg%3D%3D (Pubitemid 12089197)
3. L Klotz 2008 Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention Nat Clin Pract Urol 5 2 3 18043601 10.1038/ncpuro0993
4. SL Galper MH Chen WJ Catalona KA Roehl JP Richie AV D'Amico 2006 Evidence to support a continued stage migration and decrease in prostate cancer specific mortality J Urol 175 907 912 16469577 10.1016/S0022-5347(05)00419-2 (Pubitemid 43200015)
5. FH Schröder J Hugosson MJ Roobol TL Tammela S Ciatto V Nelen, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 1320 1328 19297566 10.1056/NEJMoa0810084
6. R Etzioni DF Penson JM Legler D di Tommaso R Boer PH Gann EJ Feuer 2002 Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer Incidente Trenes J Nat Cancer Inst 94 981 990 12096083 (Pubitemid 34814727)
7. JE Johansson O Andrén SO Andersson PW Dickman L Holmberg A Magnuson HO Adami 2004 Natural history of early, localized prostate cancer JAMA 291 2713 2719 15187052 10.1001/jama.291.22.2713 1:CAS:528:DC%2BD2cXkvVeqs7c%3D (Pubitemid 38725420)
8. PA Abrahamsson W Artibani CR Chapple M Wirth 2009 European Association of Urology position statement on screening for prostate cancer Eur Urol 56 270 271 19481336 10.1016/j.eururo.2009.05.024
9. PJ Bastian BH Carter A Bjartell M Seitz P Stanislaus F Montorsi, et al. 2009 Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 1321 1332 19286302 10.1016/j.eururo.2009.02. 028
10. DV Makarov BJ Trock EB Humphreys LA Mangold PC Walsh JI Epstein AW Partin 2007 Updated nomogram to predict pathological stage of prostate cancer given prostate-specific antigen, clinical stage, and biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005 Urology 69 1095 1101 17572194 10.1016/j.urology.2007.03.042 (Pubitemid 46891611)
11. R Choo G DeBoer L Klotz C Danjoux GC Morton E Rakovitch, et al. 2001 PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 50 615 620 11395227 10.1016/S0360-3016(01)01511-5 1:STN:280:DC%2BD3MzislOqug%3D%3D (Pubitemid 32519594)
12. R Choo L Klotz C Danjoux GC Morton G DeBoer E Szumacher, et al. 2002 Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 1664 1669 11912384 10.1016/S0022-5347(05)65174-9 (Pubitemid 34240696)
13. FK Chun A Haese SA Ahyai J Walz N Suardi U Capitanio, et al. 2008 Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men Cancer 113 701 709 18553365 10.1002/cncr.23610
14. JA Lane FC Hamdy RM Martin EL Turner DE Neal JL Donovan 2010 Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 3095 3101 21047592 10.1016/j.ejca.2010.09.016 1:STN:280:DC%2BC3cbksFChsw%3D%3D
15. RCN van den Bergh S Roemeling MJ Roobol W Roobol FH Schröder CH Bangma 2007 Prospective validation of active surveillance in prostate cancer: the PRIAS Study Eur Urol 52 1560 1563 17532115 10.1016/j.eururo.2007.05.011 (Pubitemid 350052404)
16. L Klotz 2010 Active surveillance for prostate cancer: patient selection and management Curr Oncol 17 suppl. 2 S11 S17 20882126
17. A Heidenreich J Bellmunt M Bolla S Joniau M Mason V Matveev, et al. 2011 EAU Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 61 71 21056534 10.1016/j.eururo. 2010.10.039
18. KR Ghani K Grigor DN Tulloch PR Bollina SA McNeill 2005 PSA doubling time of prostate carcinoma managed with watchful observation alone Eur Urol 47 196 201 15661414 10.1016/j.eururo.2004.07.029 (Pubitemid 40126976)
19. PC Albertsen JA Hanley GH Barrows DF Penson PDH Kowalczyk MM Sanders J Fine 2005 Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 1248 1253 16145045 10.1093/jnci/dji248 (Pubitemid 41535365)
20. JI Epstein WC Allsbrook MB Amin LL Elevad the ISUP Grading Comité 2005 The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 1228 1242 16096414 10.1097/01.pas.0000173646.99337.b1 (Pubitemid 41232997)
21. TY Chan AW Partin PC Walsh JL Epstein 2000 Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy Urology 56 823 827 11068310 10.1016/S0090-4295(00)00753-6 1:STN:280: DC%2BD3crhtlWkug%3D%3D
22. CM Herman MW Kattan M Ohori PT Scardino TM Wheeler 2001 Primary Gleason pattern as a predictor of disease progresión in Gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy Am J Surg Pathol 25 657 660 11342779 10.1097/00000478-200105000-00014 1:STN:280:DC%2BD3M3ktV2rtQ%3D%3D (Pubitemid 32423365)
23. WK Lau ML Blute DG Bostwick AL Weaver TJ Sebo H Zincke 2001 Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4 J Urol 166 1692 1697 11586204 10.1016/S0022-5347(05)65655-8 1:STN:280: DC%2BD3MrjvFWgug%3D%3D
24. JL Wright CA Salinas DW Lin S Kolb J Koopmeiners Z Feng JL Stanford 2009 Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 - 3 and Gleason 3 - 4 tumors in a population based cohort J Urol 182 2702 2707 19836772 10.1016/j.juro.2009.08.026
25. L Klotz 2008 Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention Nat Clin Parcticae Urol 5 2 3 10.1038/ncpuro0993
26. A Semjonow B Brandt F Oberpenning S Roth L Hertle 1996 Discordance Prostate Suppl 7 3 16 10.1002/(SICI)1097-0045(1996)7+<3::AID-PROS1>3.0. CO;2-T 1:STN:280:DyaK2s7gslKiug%3D%3D
27. Jarrigue V. The need for a lower total PSA cut-off value with PSA assays calibrated to the new WHO standard. Clinical Laboratory International April 2007.
28. FH Jansen M Roobol CH Bangma RH van Schaik 2008 Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection Clin Chem 54 1999 2006 18927249 10.1373/clinchem.2007.102699 1:CAS:528:DC%2BD1MXjtFejtg%3D%3D (Pubitemid 352774033)
29. C Stephan M Klaas C Müller D Schnorr SA Loening K Jung 2006 Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update Clin Chem 52 59 64 16391327 10.1373/clinchem.2005.059170 1:CAS:528:DC%2BD28XitlygsQ%3D%3D (Pubitemid 43032467)
30. C Stephan J Kramer HA Meyer G Kristiansen S Ziemer S Deger, et al. 2007 Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies BJU Int 99 1427 1431 17355366 10.1111/j.1464-410X.2007.06805.x 1:CAS:528:DC%2BD2sXotFansLo%3D (Pubitemid 47164809)
31. PR Slev SL La'ulu WL Roberts 2008 Intermethod differences in results for total PSA, free PSA, and percentage of free PSA Am J Clin Pathol 129 952 958 18480013 10.1309/JYBPMFNUF6EYY9TB 1:CAS:528:DC%2BD1cXnsFOhtLw%3D
32. C Sturgeon F Dati MJ Duffy U Hasholzner R Klapdor R Lamerz, et al. 1999 Quality requirements and control: EGTM recommendations. European Group on Tumour Markers Anticancer Res 19 2791 2794